SCM
MCRB icon

Silverarc Capital Management’s Seres Therapeutics MCRB Stock Holding History

Silverarc Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,135
Closed -$2.93K – 94
2021
Q2 		$2.93K Buy
+6,135
New +$2.59M 1.31% 26

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Silverarc Capital Management's MCRB Position: Q2 2023 in Review

Silverarc Capital Management sold out of Seres Therapeutics (MCRB) in Q2 2023, closing a stake of 11,626 shares — an estimated $1.32M sold.

Silverarc Capital Management first reported a position in MCRB in Q4 2020 and held it in 10 quarters. The position peaked at $2.67M in Q4 2021. 137 funds tracked by Wall St. Rank hold MCRB as of Q2 2023.

  • Silverarc Capital Management reported no remaining Seres Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 11,626 Seres Therapeutics shares in Q2 2023, an estimated $1.32M.
  • Silverarc Capital Management first reported a position in Seres Therapeutics in Q4 2020 and held it in 10 quarters.
  • Silverarc Capital Management's Seres Therapeutics position peaked at $2.67M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2023.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.